T1	Participants 58 120	patients with hepatitis C virus-related chronic liver disease.
T2	Participants 285 350	101 patients with hepatitis C virus-related chronic liver disease
T3	Participants 360 479	Forty-nine patients were assigned to receive UDCA (450 mg/day) over a period of 6 months and 52 to receive no treatment
T4	Participants 803 816	control group
T5	Participants 970 1020	patients who fail to respond to interferon therapy
